A U.S. Patent for “Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins” was awarded to Moderna on November 5th, 2019. The present invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility… Learn More